Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by ChiefBroncoon Mar 17, 2020 9:09am

35 Views

Post# 30816327

RE:I believe all is good

ChiefBronco wrote:
1- Us and Eu patents GVHD 2 - multiple steroids sparing patents 3- First to have fda approved GVHD life saving drug 4- shareholders get to vote for acquisition 5- acquisition only happens is private placement of 10 million is met 6- so this means we will get the money we need to complete phase 3 GVHD testing and fda approval Hold for profit I know I am GLTA

Bullboard Posts

The top 10 Canadian medical stocks